TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
Xellia Pharmaceuticals AS
Closing information (x1000 DKK)
Closing information | 2023/12 | 2022/12 | 2021/12 |
Turnover |
56,936
|
62,868
|
54,618 |
Financial expenses |
9
|
2
|
220 |
Earnings before taxes |
33,555
|
36,804
|
13,925 |
Total assets |
485,496
|
480,975
|
466,831 |
Current assets |
161,781
|
150,501
|
134,414 |
Current liabilities |
36,088
|
13,209
|
11,856 |
Equity capital |
447,173
|
465,224
|
452,113 |
- share capital |
148,027
|
157,718
|
166,462 |
Financial ratios
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Solvency |
92.1%
|
96.7%
|
96.8% |
Turnover per employee | |||
Profit as a percentage of turnover |
58.9%
|
58.5%
|
25.5% |
Return on assets (ROA) |
6.9%
|
7.7%
|
3.0% |
Current ratio |
448.3%
|
1139.4%
|
1133.7% |
Return on equity (ROE) |
7.5%
|
7.9%
|
3.1% |
Change turnover |
-2,069
|
11,119
|
-6,164 |
Change turnover % |
-4%
|
21%
|
-10% |
Chg. No. of employees | |||
Chg. No. of employees % |
Total value of public sale
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.